Literature DB >> 15200948

Perspectives on the nature of BCR-mediated survival signals.

Susan Harless Smith1, Michael Reth.   

Abstract

In the June 11 issue of Cell, Kraus et al. (2004) show, through conditional mutagenesis, that mature B cells have a drastically reduced life span in the absence of normal B cell antigen receptor (BCR) surface expression or tonic signal transduction. These studies support a role for signal transduction downstream of the BCR, rather than continued surface expression per se for the maintenance and survival of mature B cells in the periphery. Further, these studies exclude transient INF(gamma)-induced activation as a prerequisite to apoptosis in receptor-less cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15200948     DOI: 10.1016/j.molcel.2004.06.015

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  9 in total

1.  B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.

Authors:  Diana Cozma; Duonan Yu; Suchita Hodawadekar; Anna Azvolinsky; Shannon Grande; John W Tobias; Michele H Metzgar; Jennifer Paterson; Jan Erikson; Teresa Marafioti; John G Monroe; Michael L Atchison; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

2.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Jonathan W Friedberg; Jeff Sharman; John Sweetenham; Patrick B Johnston; Julie M Vose; Ann Lacasce; Julia Schaefer-Cutillo; Sven De Vos; Rajni Sinha; John P Leonard; Larry D Cripe; Stephanie A Gregory; Michael P Sterba; Ann M Lowe; Ronald Levy; Margaret A Shipp
Journal:  Blood       Date:  2009-11-17       Impact factor: 22.113

3.  Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

Authors:  Ryan M Young; Ian R Hardy; Raedun L Clarke; Nicolai Lundy; Polly Pine; Brian C Turner; Terry A Potter; Yosef Refaeli
Journal:  Blood       Date:  2008-11-03       Impact factor: 22.113

4.  Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.

Authors:  Qingshan Yang; Lisa S Chen; Min Jin Ha; Kim-Anh Do; Sattva S Neelapu; Varsha Gandhi
Journal:  Clin Cancer Res       Date:  2016-06-24       Impact factor: 12.531

5.  SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.

Authors:  Linfeng Chen; Stefano Monti; Przemyslaw Juszczynski; John Daley; Wen Chen; Thomas E Witzig; Thomas M Habermann; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2007-11-15       Impact factor: 22.113

6.  BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.

Authors:  Przemyslaw Juszczynski; Linfeng Chen; Evan O'Donnell; Jose M Polo; Stella M Ranuncolo; Riccardo Dalla-Favera; Ari Melnick; Margaret A Shipp
Journal:  Blood       Date:  2009-10-23       Impact factor: 22.113

7.  Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells.

Authors:  Adam L Palazzo; Erik Evensen; Ying-Wen Huang; Alessandra Cesano; Garry P Nolan; Wendy J Fantl
Journal:  PLoS One       Date:  2011-10-10       Impact factor: 3.240

Review 8.  Altered N-Linked Glycosylation in Follicular Lymphoma and Chronic Lymphocytic Leukemia: Involvement in Pathogenesis and Potential Therapeutic Targeting.

Authors:  Nurit Hollander; Joseph Haimovich
Journal:  Front Immunol       Date:  2017-08-02       Impact factor: 7.561

9.  Variant B cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes.

Authors:  Nicola J Weston-Bell; Francesco Forconi; Hanneke C Kluin-Nelemans; Surinder S Sahota
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.